
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Ridinilazole
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : $50.0 million
Deal Type : Financing
Summit Announces Agreement For a Fundraising of Approximately $50 Million
Details : Funds support continued patient enrolment into the Ri-CoDIFy Phase 3 clinical trial program of ridinilazole for the treatment of Clostridium difficile infection; launch of Ridinilazole and Development of early-stage research projects using the Company’...
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Undisclosed
October 02, 2020
Lead Product(s) : Ridinilazole
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : $50.0 million
Deal Type : Financing

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Docusate Potassium
Therapeutic Area : Gastroenterology
Study Phase : Approved FDF
Recipient : Summit Pharmaceuticals Europe Srl
Deal Size : Undisclosed
Deal Type : Acquisition
Details : Quest will add the Enemeez and DocuSol brands of bowel care products, to its' portfolio of self-care products.
Product Name : Enemeez
Product Type : Miscellaneous
Upfront Cash : Undisclosed
June 24, 2020
Lead Product(s) : Docusate Potassium
Therapeutic Area : Gastroenterology
Highest Development Status : Approved FDF
Recipient : Summit Pharmaceuticals Europe Srl
Deal Size : Undisclosed
Deal Type : Acquisition

Contact Us!